Results 1 to 10 of about 61,117 (342)

Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances? [PDF]

The Journal of Clinical Hypertension
The obesity pandemic, with its associated comorbidities of hypertension and diabetes, constitutes a global public health issue. Importantly, there is an increasing prevalence of aldosterone excess related to obesity and resultant poor health outcomes ...
Houry Puzantian, Raymond Townsend, Shweta Bansal   +2 more
doaj   +4 more sources

Regulation of Klotho Production by Mineralocorticoid Receptor Signaling in Renal Cell Lines [PDF]

Biomolecules
Through the mineralocorticoid receptor, aldosterone controls extracellular volume and arterial blood pressure by stimulating Na+ absorption and K+ secretion in epithelial cells of the kidney, colon, and several glands.
Elena Kohm, Martina Feger, Michael Föller   +2 more
doaj   +2 more sources

Mineralocorticoid receptor antagonists reduce inflammatory signaling independent of myofiber mineralocorticoid receptor [PDF]

Endocrine and Metabolic Science
Chronic inflammation is a feature of Duchenne muscular dystrophy (DMD), a degenerative striated muscle disease. Mineralocorticoid receptor (MR) antagonists (MRAs) have demonstrated clinical benefit on later onset DMD cardiomyopathy, and preclinical ...
Jeovanna Lowe, Arden B. Piepho, Chetan K. Gomatam, Peyton Debell, Megan N. Ballinger, Jill A. Rafael-Fortney   +5 more
doaj   +2 more sources

Does Mineralocorticoid Receptor Antagonism Prevent Calcineurin Inhibitor-Induced Nephrotoxicity? [PDF]

Frontiers in Medicine, 2017
Calcineurin inhibitors have markedly reduced acute rejection rates in renal transplantation, thus significantly improved short-term outcome. The beneficial effects are, however, tampered by acute and chronic nephrotoxicity leading to interstitial ...
Line Aas Mortensen, Line Aas Mortensen, Claus Bistrup, Claus Bistrup, Helle Charlotte Thiesson, Helle Charlotte Thiesson   +5 more
doaj   +2 more sources

Mineralocorticoid Receptor Blocker Prevents Mineralocorticoid Receptor–Mediated Inflammation by Modulating Transcriptional Activity of Mineralocorticoid Receptor–p65–Signal Transducer and Activator of Transcription 3 Complex [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Mineralocorticoid receptor (MR) induces cardiac inflammation cooperatively with nuclear factor‐κB and signal transducer and activator of transcription 3 (STAT3); MR blockers exert anti‐inflammatory effects.
Naoto Kuyama, Satoshi Araki, Koichi Kaikita, Nobuhiro Nakanishi, Naoya Nakashima, Shinsuke Hanatani, Yuichiro Arima, Masahiro Yamamoto, Taishi Nakamura, Eiichiro Yamamoto, Kenichi Matsushita, Kunihiko Matsui, Kenichi Tsujita   +12 more
doaj   +2 more sources

Mineralocorticoid receptor activation contributes to intestinal fibrosis through neutrophil gelatinase-associated lipocalin in preclinical models [PDF]

Nature Communications
Intestinal fibrosis is a common complication in inflammatory bowel diseases with no specific therapy. Because mineralocorticoid receptor antagonism prevented inflammation and fibrosis in extra-intestinal organs, we aimed to evaluate mineralocorticoid ...
Asma Amamou, Mathilde Leboutte, Jonathan Breton, David Ribet, Pierre-Alain Thiebaut, Christine Bôle-Feysot, Charlène Guérin, Kanhia Aublé, Elise Rebollo, Lise Ratel, Benjamin Bonnard, Alexis Goichon, Louison Leblond, Moutaz Aziz, Elodie Fermant, Frédéric Jaisser, Guillaume Savoye, Rachel Marion-Letellier   +17 more
doaj   +2 more sources

Mineralocorticoid Receptor Antagonism Reduces Atrial Arrhythmias Post‐Cardiac Surgery and Attenuates Atrial Stress Responses to Cardioplegic Arrest [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Postoperative atrial fibrillation occurs in ~40% after cardiac surgery. Mineralocorticoid receptor antagonists (MRA) are known to reduce chronic atrial fibrillation (AF) development and burden.
Sina Danesh, Fazal Khan, Trevor Chopko, Aurora Lee, Ran Huo, Shuyang Lu, Vincy Tam, Wenbin Gao, Austin Todd, Joseph J. Maleszewski, Francis D. Pagani, Hartzell Schaff, Y. Eugene Chen, Paul A. Friedman, Hakan Oral, Marco Metra, Bertram Pitt, Ienglam Lei, Paul C. Tang   +18 more
doaj   +2 more sources

Mineralocorticoid Receptor Antagonists [PDF]

International Cardiovascular Forum Journal, 2019
Two mineralocorticoid receptor antagonists, spironolactone and eplerenone, are currently approved by the FDA. Several non-steroid based ligands are in clinical trials for indications including heart failure, hypertension and diabetic kidney disease, and even more structurally distinct chemical series are reported in the literature with preclinical data
Anneli, Nordqvist, Kenneth L, Granberg
  +5 more sources

Administration of finerenone in chronic kidney disease [PDF]

Journal of Nephropathology, 2023
Spironolactone is a first-generation and non-selective mineralocorticoid receptor antagonist (MRA). It is extensively well-studied and recommended due to increased accessibility for patients.
Mohsen Akhavan Sepahi, Elham Emami, Akshaya Ann Joseph, Shakiba Hassanzadeh, Mohammad Reza Razavi   +4 more
doaj   +1 more source

Vascular cell‐specific roles of mineralocorticoid receptors in pulmonary hypertension

Pulmonary Circulation, 2021
Abnormalities that characterize pulmonary arterial hypertension include impairment in the structure and function of pulmonary vascular endothelial and smooth muscle cells.
Divya P. Menon, Guanming Qi, Seung K. Kim, M. Elizabeth Moss, Krishna C. Penumatsa, Rod R. Warburton, Deniz Toksoz, Jamie Wilson, Nicholas S. Hill, Iris Z. Jaffe, Ioana R. Preston   +10 more
doaj   +1 more source